Search scope:
排序: Display mode:
Vaccine therapies for chronic hepatitis B: can we go further?
Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan
Frontiers of Medicine 2014, Volume 8, Issue 1, Pages 17-23 doi: 10.1007/s11684-014-0313-7
Chronic hepatitis B is a major health burden worldwide.antiviral treatment, therapeutic vaccination is a promising new strategy for the control of chronic hepatitisB.On the basis of the major specific and non-specific immune dysregulations and defects in chronic hepatitisB patients, this paper presents the peptide and protein-based, DNA-based, cell-based, and antigen-antibody-based
Keywords: chronic hepatitis B therapeutic antigen-antibody complexes DNA vaccine
Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM ,
Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 277-283 doi: 10.1007/s11684-009-0047-0
Keywords: hepatitis B virus gene variation hepatitis B surface antigen immune escape enzyme-linked immunosorbent
Experimental Studies on Recombinant Hepatitis B Immunogenic Complex Therapeutic Vaccine (YIC)
Wenyu mei,He Lifang,Qu Di,Ma Zhangmei,Yao Xin
Strategic Study of CAE 1999, Volume 1, Issue 1, Pages 38-42
A therapeutic vaccine composed of HBsAg complexed to anti-HBs (IC) has been developed for viral hepatitisB.In addi-tion, this complex was used to immunize an HBsAg low-responder mouse strain (B10.S).Data showed that this immunogenic complex has promising potential to be used for the treatment of hepatitisB patients.
Keywords: hepatitis B therapeutic vaccine antigen-antibody complex immune responses
Current hepatitis B treatment guidelines and future research directions
Jonathan Skupsky,Ke-Qin Hu
Frontiers of Medicine 2014, Volume 8, Issue 2, Pages 145-157 doi: 10.1007/s11684-014-0335-1
Hepatitis B virus (HBV) infection causes a tremendous clinical burden across the world with more than
Keywords: chronic hepatitis B HBV treatment guidelines APASL guidelines EASL guidelines AASLD guidelines
Frontiers of Medicine 2022, Volume 16, Issue 1, Pages 111-125 doi: 10.1007/s11684-021-0854-5
Keywords: COVID-19 chronic hepatitis B liver injury coagulation dysfunction
Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China
Rui Yu,Rong Fan,Jinlin Hou
Frontiers of Medicine 2014, Volume 8, Issue 2, Pages 135-144 doi: 10.1007/s11684-014-0331-5
Chronic hepatitis B is a major health problem in China.The universal vaccination program since 1992 has changed the epidemiology of hepatitis B virus infectionThe most prevalent hepatitis B virus strains in China are genotypes B and C, whereas those in westernChronic hepatitis B poses a heavy burden to the society in China.
Keywords: chronic hepatitis B epidemiology prevention treatment
Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang
Frontiers of Medicine 2014, Volume 8, Issue 2, Pages 250-253 doi: 10.1007/s11684-014-0333-3
Keywords: acute-on-chronic liver failure submassive necrosis viral hepatitis B esophageal variceal bleeding liver
Correlation between viral load and liver cirrhosis in chronic hepatitis B patients
Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,
Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 271-276 doi: 10.1007/s11684-009-0054-1
Keywords: hepatitis B chronic viral load liver cirrhosis
MicroRNAs and hepatitis viruses
Gang LI MD , Xiaojia XIONG MM ,
Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 265-270 doi: 10.1007/s11684-009-0055-0
Keywords: microRNA hepatitis B virus hepatitis C virus
Current advances in the elimination of hepatitis B in China by 2030
Shuye Zhang, Fusheng Wang, Zheng Zhang
Frontiers of Medicine 2017, Volume 11, Issue 4, Pages 490-501 doi: 10.1007/s11684-017-0598-4
With its 78 million chronic carriers, hepatitis B virus (HBV) infection is still one of the leadingefficacious in suppressing HBV replication; however, it fails to completely cure patients with chronic hepatitisB and even requires lifelong treatment.Work is still needed to eliminate hepatitis B in China by 2030.
Keywords: HBV CHB biomarker functional cure coinfection
Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia
Frontiers of Medicine 2017, Volume 11, Issue 4, Pages 502-508 doi: 10.1007/s11684-017-0590-z
Although the efficacy of nucleos(t)ide analogue (NA) has been confirmed for treatment of chronic hepatitisB, long-term therapy has been recommended due to the high frequency of off-therapy viral DNA reboundIn this review, the RNA virion-like particles of hepatitis B virus (HBV) are integrated into the lifeIn contrast to hepatitis B surface antigen (HBsAg) that can originate from either the cccDNA or the integratedB, to distinguish the “functional cure” characterized as serum HBsAg loss with or without
Keywords: chronic hepatitis B serum HBV RNA nucleos(t)ide analogs virological response para-functional cure
New perspective on the natural course of chronic HBV infection
Yong-Yuan Zhang,Ke-Qin Hu,Zhongping Duan
Frontiers of Medicine 2014, Volume 8, Issue 2, Pages 129-134 doi: 10.1007/s11684-014-0339-x
Chronic hepatitis B virus (HBV) infection is a significant threat to public health and an enormousHBV infection is conventionally viewed as an uninterrupted process that is usually marked by HBV e antigenmutant becomes predominant in the viral population following elimination of the wild-type virus in duck hepatitisB virus-chronically infected animals.
Keywords: hepatitis B virus chronic HBV infection natural course hepatitis B seroconversion
Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG,
Frontiers of Medicine 2010, Volume 4, Issue 4, Pages 419-429 doi: 10.1007/s11684-010-0160-0
Keywords: hepatitis B virus hepatocellular carcinoma mutation genotype haplotype
Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen
Frontiers of Medicine 2014, Volume 8, Issue 2, Pages 217-226 doi: 10.1007/s11684-014-0326-2
Keywords: hepatocellular carcinoma (HCC) interaction miRNA-122-binding site IL-1A rs3783553 hepatitis B virus (
Frontiers of Medicine 2022, Volume 16, Issue 2, Pages 285-294 doi: 10.1007/s11684-021-0843-8
Keywords: CAR-T cell therapy refractory diffuse large B-cell lymphoma cytokine release syndrome dose-limiting
Title Author Date Type Operation
Vaccine therapies for chronic hepatitis B: can we go further?
Yumei Wen, Xuanyi Wang, Bin Wang, Zhenhong Yuan
Journal Article
Preparation, identification, and clinical application of anti-HBs monoclonal antibody that binds both wild-type and immune escape mutant HBsAgs
Fanghe LI BM , Chunyan ZHANG MS , Jinghua LIU MS , Xiaoyan ZHANG MS , Bing YAN , Bo ZHANG MS , Yongguo HUANG MS , Jingsong GONG BM , Yan CHEN BM ,
Journal Article
Experimental Studies on Recombinant Hepatitis B Immunogenic Complex Therapeutic Vaccine (YIC)
Wenyu mei,He Lifang,Qu Di,Ma Zhangmei,Yao Xin
Journal Article
Current hepatitis B treatment guidelines and future research directions
Jonathan Skupsky,Ke-Qin Hu
Journal Article
Clinical characteristics and risk factors of COVID-19 patients with chronic hepatitis B: a multi-center
Journal Article
Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China
Rui Yu,Rong Fan,Jinlin Hou
Journal Article
Comprehensive treatment of acute-on-chronic liver failure in a patient with hepatitis B: a case report
Lei Li,Yimei Liu,Tiancheng Luo,Jian Zhou,Yingyong Hou,Xizhong Shen,Jiyao Wang
Journal Article
Correlation between viral load and liver cirrhosis in chronic hepatitis B patients
Lili LIU MM , Jiyao WANG MD , Weimin SHE MM ,
Journal Article
Current advances in the elimination of hepatitis B in China by 2030
Shuye Zhang, Fusheng Wang, Zheng Zhang
Journal Article
Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide
Fengmin Lu, Jie Wang, Xiangmei Chen, Dongping Xu, Ningshao Xia
Journal Article
New perspective on the natural course of chronic HBV infection
Yong-Yuan Zhang,Ke-Qin Hu,Zhongping Duan
Journal Article
Association of novel mutations and heplotypes in the preS region of hepatitis B virus with hepatocellular
Jia-Xin XIE, Jian-Hua YIN, Qi ZHANG, Rui PU, Wen-Ying LU, Hong-Wei ZHANG, Guang-Wen CAO, Jun ZHAO, Hong-Yang WANG,
Journal Article
Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitisB virus mutations with hepatocellular carcinoma risk
Du Yan, Han Xue, Pu Rui, Xie Jiaxin, Zhang Yuwei, Cao Guangwen
Journal Article